In recent years, inhibiting PCSK9, a serine proteinase that regulates cholesterol metabolism, has been demonstrated to be a method enhancing the antitumor effects of anti-PD-1/PD-L1 treatment to ...

AstraZeneca and Merck are the main drugmakers testing oral versions of so-called PCSK9 Inhibitors, which reduce levels of low-density lipoprotein (LDL) cholesterol, or what is known as "bad ...

A new study conducted at Cedars-Sinai reveals how the cholesterol-reducing drug evolocumab prevents heart attacks in people ...

"We've had PCSK9 inhibitors on the market in the United States for 10 years," said investigator Michael Koren, MD, a cardiologist and CEO of the ENCORE Research Group in Jacksonville, Florida.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package ...

AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase 3 programme, removing a competitor to Novartis' rival therapy Leqvio. Like Leqvio ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

A once-daily oral PCSK9 inhibitor reduced LDL in patients with hypercholesterolemia. Safety and tolerability profiles were favorable, according to investigators. CHICAGO — In a phase 2b study ...

AstraZenca is testing a once-daily PCSK9 inhibitor, currently known as AZD0780. After 12 weeks of use alongside standard statin therapy, the pill reduced low-density lipoprotein cholesterol ...

Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. One year after dropping a base editing candidate over a safety signal, the biotech has shown its Eli Lilly-partnered ...

DelveInsight's "LEQVIO Market Size, Forecast, and Market Insight Report" highlights the details around LEQVIO, which is a ...